| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Grant revenue | 1,848 | 118,111 | 162,463 | 354,621 |
| Research and development | 1,638,917 | 1,912,213 | 2,483,066 | 2,846,399 |
| General and administrative | 1,480,319 | 1,593,671 | 1,764,979 | 1,605,238 |
| Total operating expenses | 3,119,236 | 3,505,884 | 4,248,045 | 4,451,637 |
| Loss from operations | -3,117,388 | -3,387,773 | -4,085,582 | -4,097,016 |
| Interest income, net | 150,669 | 178,027 | 204,726 | 348,741 |
| Foreign currency (loss) gain | -5,691 | -29,124 | -51,803 | -35,494 |
| Total other income | 144,978 | 148,903 | 152,923 | 313,247 |
| Net loss | -2,972,410 | -3,238,870 | -3,932,659 | -3,783,769 |
| Foreign currency translation | -1,117 | -1,681 | 643 | 23,557 |
| Total comprehensive loss | -2,973,527 | -3,240,551 | -3,932,016 | -3,760,212 |
| Earnings per share, basic | -0.47 | -0.53 | -0.66 | -0.64 |
| Earnings per share, diluted | -0.47 | -0.53 | -0.66 | -0.64 |
| Weighted average number of shares outstanding, basic | 6,372,938 | 6,083,329 | 5,993,866 | 5,939,755 |
| Weighted average number of shares outstanding, diluted | 6,372,938 | 6,083,329 | 5,993,866 | 5,939,755 |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)